GlobeImmune raises $17.5 million
This article was originally published in Scrip
Executive Summary
GlobeImmune, a private US biopharmaceutical company focused on cancer and infectious diseases, has raised $17.5 million in a series A round, led by new investors Generali Financial Holding and BSI SA.